| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 3,165 | 3,150 | ||
| General and administrative expenses | 1,024 | 1,464 | ||
| Marketing expenses | 120 | 182 | ||
| Total operating expenses | 4,309 | 4,796 | ||
| Operating loss | -4,309 | -4,796 | ||
| Other (income) expense, net | 136 | -96 | ||
| Change in fair value of derivative liabilities | - | 107 | ||
| Finance income, net | 2 | 29 | ||
| Net loss | -4,171 | -4,756 | ||
| Foreign currency translation adjustment | 8 | 29 | ||
| Comprehensive loss for the period | -4,163 | -4,727 | ||
| Basic net loss per share | 4.64 | 9.62 | ||
| Diluted net loss per share | 4.64 | 9.62 | ||
| Weighted-average shares used to compute basic net loss per share | 899,410 | 494,504 | ||
| Weighted-average shares used to compute diluted net loss per share | 899,410 | 494,504 | ||
Glucotrack, Inc. (GCTK)
Glucotrack, Inc. (GCTK)